ערך בספרים למניה: tnfpharma.com (TNFA)

TNF Pharmaceuticals is implementing bioinformatics and automation for protein analysis in drug development. The book value per share on GURU.Markets demonstrates fundamental management quality, where the 17.47 mark serves as a key metric. The company is developing methods to combat cellular senescence through medical funds, focusing on the clinical validation of molecules within B2B partnerships.

To assess the financial stability of TNF Pharmaceuticals (TNFA), it is essential to track net asset capitalization, which supports the development of the biopharmaceutical ecosystem's patent perimeter. This metric is calculated as the ratio of equity to the number of shares outstanding; therefore, this book value per share chart clearly demonstrates the pace of asset accumulation and the efficiency of reinvesting profits into the development of targeted inhibitors.